A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Atezolizumab (Primary) ; Lenalidomide; Obinutuzumab
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 02 Apr 2016 Planned End Date changed from 1 Oct 2018 to 1 Jan 2020 as reported by ClinicalTrials.gov.
- 02 Apr 2016 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2020 as reported by ClinicalTrials.gov.
- 18 Dec 2015 New trial record